Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Glenmark Pharmaceuticals Limited (NSE: GLENMARK), ISIN INE935A01035 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
GLENMARK last traded at ₹2689.10 (+3.63%), with a 52-week range of ₹1807.00 to ₹2714.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 46.65%, FIIs 21.51%, DIIs 17.63%, mutual funds 15.61%.
EquiSense Score (ECS): 44/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.